Amundi Invests $166,000 in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Amundi bought a new position in Sage Therapeutics, Inc. (NASDAQ:SAGE) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 28,327 shares of the biopharmaceutical company’s stock, valued at approximately $166,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. US Bancorp DE lifted its position in shares of Sage Therapeutics by 22.3% in the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 2,268 shares during the period. Geode Capital Management LLC lifted its position in shares of Sage Therapeutics by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock worth $8,975,000 after purchasing an additional 3,757 shares during the period. Quest Partners LLC lifted its position in shares of Sage Therapeutics by 56.3% in the 3rd quarter. Quest Partners LLC now owns 18,381 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 6,618 shares during the period. SG Americas Securities LLC lifted its position in shares of Sage Therapeutics by 57.7% in the 4th quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 8,228 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Sage Therapeutics by 2.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 462,309 shares of the biopharmaceutical company’s stock worth $2,510,000 after purchasing an additional 10,116 shares during the period. 99.22% of the stock is owned by hedge funds and other institutional investors.

Sage Therapeutics Stock Up 1.1 %

Shares of SAGE stock opened at $8.10 on Friday. The company has a 50 day moving average price of $7.36 and a 200-day moving average price of $6.71. Sage Therapeutics, Inc. has a 52 week low of $4.62 and a 52 week high of $20.32. The firm has a market capitalization of $498.00 million, a PE ratio of -1.23 and a beta of 0.82.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. Analysts anticipate that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on SAGE shares. Scotiabank decreased their price target on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating for the company in a research note on Wednesday, February 12th. Piper Sandler decreased their price target on shares of Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, January 2nd. Wedbush reiterated a “neutral” rating and issued a $6.00 price target on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Stifel Nicolaus decreased their price target on shares of Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating for the company in a research note on Monday, December 16th. Finally, Bank of America started coverage on shares of Sage Therapeutics in a research note on Tuesday, March 11th. They issued an “underperform” rating and a $5.00 price target for the company. Three research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $8.81.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.